Paxil CR Bioequivalence Study Brazil
Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablet With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fasted Administration in Healthy Volunteers for Both Genders.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Full title: Relative bioavailability study between the formulations: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation) and Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation), fasted administration in healthy volunteers for both genders.
The study is open, randomized, crossover in steady state and the volunteers received multiple doses of the drug test and reference (two periods of drug administration).
The population is composed of 60 healthy volunteers, adult of both gender, with age between 18 and 40 years, with a body mass index (BMI) between 18.5 and 27. Volunteers have weight above than 50 kg. 50% of the volunteers recruited are female and 50% male. There are not restrictions regarding the ethnic group.The relative bioavailability of the formulations after oral administration in steady state will be evaluated based on statistical comparisons of relevant pharmacokinetic parameters obtained from data of concentration of drug in blood. The concentration of Paroxetine hydrochloride (controlled release) will be measured by an appropriate analytical method and valid after the drug administration.The Pharmacokinetic samples will be collected at steady state in each fasting period. The safety assessment will include evaluation and clinical monitoring, vital signs monitoring, ECG, and laboratory tests. Adverse events will be monitored throughout the study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30110-014
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
EXCLUSION CRITERIA:
- hypersensitivity to the study drug or to compounds chemically related;
- history of serious adverse events;
- concurrent or recent use of other antidepressives, schizophrenia, anticonvulsant;
- History of liver, heart, gastrointestinal or renal illness;
- ECG findings not recommended according to the investigator judgement;
- The volunteer ingests more than 5 cups of coffee or tea a day.
INCLUSION CRITERIA:
- Man and woman (since they are not pregnant or breastfeeding);
- age between 18 and 40 years;
- non-smoker and not addict;
- mass index between 18,5 and 27;
- good health conditions or without significant illness, by judgement of a legally qualified professional;
- sign the informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Paxil CR Reference
Reference drug administration followed by test drug administration
|
Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
|
|
Aktiv komparator: Paxil CR Test
Test drug administration followed by Reference drug administration
|
Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Area Under the Curve_steady-state
Tidsram: Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC).
The AUC_steady-state (ss) is the area under the curve during the steady-state period.
The AUC_ss is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
ng, nanogram; h, hour; ml, milliliter.
ng.h/ml, nanograms per hour per milliliter.
|
Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
|
Cmin_steady-state
Tidsram: Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
Cmin_steady-state (ss) is defined as the minimum concentration of a drug observed after its administration in steady-state.
Cmin_ss is one of the parameters of particular use in estimating the bioavailability of drugs, for studies employing multiple doses.
|
Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
|
Cmax_steady-state
Tidsram: Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
Cmax_steady-state (ss) is defined as the maximum or "peak" concentration of a drug observed after its administration, in steady-state.
Cmax_ss is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.
|
Days 14 to 17 (Period 1) and Days 23 to 24 (Period 2)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 113939
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Depressiv sjukdom
-
University Medical Center GoettingenAvslutadMajor depressiv sjukdom | Depressiv episodTyskland
-
York UniversityCentre for Addiction and Mental HealthUpphängdStörning, major depressivKanada
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutadDepressiv sjukdom, allvarlig depressiv sjukdomFörenta staterna
-
Shalvata Mental Health CenterOkändSTOR depressiv sjukdomIsrael
-
Omni C&SAnmälan via inbjudanDepressiv sjukdom | Major depressiv sjukdom | Depressiv episodKorea, Republiken av
-
Seasons Biotechnology (Taizhou) Co., Ltd.AvslutadMajor depressiv sjukdom (MDD)Indien
-
Repurposed Therapeutics, Inc.Okänd
-
GlaxoSmithKlineAvslutadMajor depressiv sjukdom (MDD)Förenta staterna
-
University of WarsawHar inte rekryterat ännuMåttlig depressiv episod | Mild depressiv episod
-
Seasons Biotechnology (Taizhou) Co., Ltd.AvslutadMajor depressiv sjukdom (MDDIndien
Kliniska prövningar på Test formulation
-
Yonsei UniversityAvslutadPostprandial hyperglykemi
-
Clinical Nutrition Research Centre, SingaporeAvslutad
-
University of MichiganAvslutadAntidepressiva medel som orsakar negativa effekter vid terapeutisk användningFörenta staterna
-
Istanbul Medipol University HospitalAvslutad
-
First Affiliated Hospital Xi'an Jiaotong UniversitySecond Affiliated Hospital of Xi'an Jiaotong UniversityHar inte rekryterat ännu
-
Centre Hospitalier de CornouailleCentre Hospitalier Régional et Universitaire de BrestAvslutad
-
Johnson & Johnson Vision Care, Inc.AvslutadKorrigering av brytningsfelFörenta staterna
-
Coloplast A/SAvslutad
-
Universidad de AntioquiaBarts and the London School of Medicine and Dentistry; Instituto Colombiano... och andra samarbetspartnersAvslutadLivmoderhalscancer | Cervikala abnormiteter | Cervikal intraepitelial neoplasi grad 2/3Colombia
-
Coloplast A/SAvslutadIleostomi - StomiDanmark